The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Acid β‐glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter α‐synuclein processing
Open accessAbstract
Objective: Heterozygous mutations in the GBA1 gene elevate the risk of Parkinson disease and dementia with Lewy bodies; both disorders are characterized by misprocessing of α‐synuclein (SNCA). A loss in lysosomal acid–β‐glucosidase enzyme (GCase) activity due to biallelic GBA1 mutations underlies Gaucher disease. We explored mechanisms for the gene's association with increased synucleinopathy risk. Methods: We analyzed the effects of wild‐type (WT) and several GBA mutants on SNCA in cellular and in vivo models using biochemical and immunohistochemical protocols. Results: We observed that overexpression of all GBA mutants examined (N370S, L444P, D409H, D409V, E235A, and E340A) significantly raised human SNCA levels to 121 to 248% of vector control (p < 0.029) in neural MES23.5 and PC12 cells, but without altering GCase activity. Overexpression of WT GBA in neural and HEK293‐SNCA cells increased GCase activity, as expected (ie, to 167% in MES‐SNCA, 128% in PC12‐SNCA, and 233% in HEK293‐SNCA; p < 0.002), but had mixed effects on SNCA. Nevertheless, in HEK293‐SNCA cells high GCase activity was associated with SNCA reduction by ≤32% (p = 0.009). Inhibition of cellular GCase activity (to 8–20% of WT; p < 0.0017) did not detectably alter SNCA levels. Mutant GBA‐induced SNCA accumulation could be pharmacologically reversed in D409V‐expressing PC12‐SNCA cells by rapamycin, an autophagy‐inducer (≤40%; 10μM; p < 0.02). Isofagomine, a GBA chaperone, showed a related trend. In mice expressing two D409V gba knockin alleles without signs of Gaucher disease (residual GCase activity, ≥20%), we recorded an age‐dependent rise of endogenous Snca in hippocampal membranes (125% vs WT at 52 weeks; p = 0.019). In young Gaucher disease mice (V394L gba+/+//prosaposin[ps]‐null//ps‐transgene), which demonstrate neurological dysfunction after age 10 weeks (GCase activity, ≤10%), we recorded no significant change in endogenous Snca levels at 12 weeks of age. However, enhanced neuronal ubiquitin signals and axonal spheroid formation were already present. The latter changes were similar to those seen in three week‐old cathepsin D‐deficient mice. Interpretation: Our results demonstrate that GBA mutants promote SNCA accumulation in a dose‐ and time‐dependent manner, thereby identifying a biochemical link between GBA1 mutation carrier status and increased synucleinopathy risk. In cell culture models, this gain of toxic function effect can be mitigated by rapamycin. Loss in GCase activity did not immediately raise SNCA concentrations, but first led to neuronal ubiquitinopathy and axonal spheroids, a phenotype shared with other lysosomal storage disorders. ANN NEUROL 2011;
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,416
Self-citationDopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models
Sarkar, S., Perlstein, E. O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R. L., Webster, J. A., Lewis, T. A., O'Kane, C. J., Schreiber, S. L., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio883 · Cited by 596
Saftig, P., Hetman, M., Schmahl, W., Weber, K., Heine, L., Mossmann, H., Köster, A., Hess, B., Evers, M., & von Figura, K. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00029.x · Cited by 438
Self-citationMollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382
Self-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Sharon, R., Goldberg, M. S., Bar-Josef, I., Betensky, R. A., Shen, J., & Selkoe, D. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171300598 · Cited by 328
Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies
Schlossmacher, M. G., Frosch, M. P., Gai, W. P., Medina, M., Sharma, N., Forno, L., Ochiishi, T., Shimura, H., Sharon, R., Hattori, N., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61113-3 · Cited by 325
Self-citationDeciphering the role of heterozygous mutations in genes associated with parkinsonism
Klein, C., Lohmann-Hedrich, K., Rogaeva, E., Schlossmacher, M. G., & Lang, A. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70174-6 · Cited by 309
Self-citationSevlever, D., Jiang, P., & Yen, S.-H. C. (2008) · Biochemistry · doi:10.1021/bi800699v · Cited by 305
Kuo, Y.-M., Li, Z., Jiao, Y., Gaborit, N., Pani, A. K., Orrison, B. M., Bruneau, B. G., Giasson, B. I., Smeyne, R. J., Gershon, M. D., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq038 · Cited by 286
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo
Cullen, V., Lindfors, M., Ng, J., Paetau, A., Swinton, E., Kolodziej, P., Boston, H., Saftig, P., Woulfe, J., Feany, M. B., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-5 · Cited by 279
Self-citationGATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein
Scherzer, C. R., Grass, J. A., Liao, Z., Pepivani, I., Zheng, B., Eklund, A. C., Ney, P. A., Ng, J., McGoldrick, M., Mollenhauer, B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802437105 · Cited by 270
Self-citationLysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity
Qiao, L., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., Yacoubian, T. A., Wilson, S., Xie, Z.-L., Speake, L. D., Parks, R., Crabtree, D., et al. (2008) · Molecular Brain · doi:10.1186/1756-6606-1-17 · Cited by 263
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease
Clark, L. N., Ross, B. M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000276989.17578.02 · Cited by 252
Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease
Lieberman, R. L., Wustman, B. A., Huertas, P., Powe, A. C., Pine, C. W., Khanna, R., Schlossmacher, M. G., Ringe, D., & Petsko, G. A. (2007) · Nature Chemical Biology · doi:10.1038/nchembio850 · Cited by 245
Self-citationGlucocerebrosidase mutations are an important risk factor for Lewy body disorders
Goker-Alpan, O., Giasson, B. I., Eblan, M. J., Nguyen, J., Hurtig, H. I., Lee, V. M.-Y., Trojanowski, J. Q., & Sidransky, E. (2006) · Neurology · doi:10.1212/01.wnl.0000230215.41296.18 · Cited by 230
Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder
Klein, C., & Schlossmacher, M. G. (2007) · Neurology · doi:10.1212/01.wnl.0000271880.27321.a7 · Cited by 211
Self-citationGlucocerebrosidase Gene Mutations: A Risk Factor for Lewy Body Disorders
Mata, I. F., Samii, A., Schneer, S. H., Roberts, J. W., Griffith, A., Leis, B. C., Schellenberg, G. D., Sidransky, E., Bird, T. D., Leverenz, J. B., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.68 · Cited by 207
Association of Glucocerebrosidase Mutations With Dementia With Lewy Bodies
Clark, L. N., Kartsaklis, L. A., Wolf Gilbert, R., Dorado, B., Ross, B. M., Kisselev, S., Verbitsky, M., Mejia-Santana, H., Cote, L. J., Andrews, H., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.54 · Cited by 202
Manning-Boğ, A. B., Schüle, B., & Langston, J. W. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.06.009 · Cited by 176
Viable Mouse Models of Acid β-Glucosidase Deficiency
Xu, Y.-H., Quinn, B., Witte, D., & Grabowski, G. A. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63566-3 · Cited by 170
Self-citationCrawford, G., Le, W., Smith, R., Xie, W., Stefani, E., & Appel, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-09-03392.1992 · Cited by 164
Brás, J., Singleton, A., Cookson, M., & Hardy, J. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06709.x · Cited by 145
Xu, Y. H., Sun, Y., Ran, H., Quinn, B., Witte, D. P., & Grabowski, G. A. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.12.014 · Cited by 139
Self-citationZheng, W., Padia, J. K., Urban, D. J., Jadhav, A., Göker-Alpan, Ö., Simeonov, A. M., Goldin, E., Auld, D. S., LaMarca, M. E., Inglese, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705637104 · Cited by 137
Sun, Y., Liou, B., Ran, H., Skelton, M. R., Williams, M. T., Vorhees, C. V., Kitatani, K., Hannun, Y. A., Witte, D. P., Xu, Y.-H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp580 · Cited by 133
Self-citationCeramide as an Activator Lipid of Cathepsin D
Heinrich, M., Wickel, M., Winoto‐Morbach, S., Schneider‐Brachert, W., Weber, T., Brunner, J., Säftig, P., Peters, C., Krönke, M., & Schütze, S. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-46826-3_33 · Cited by 126
Analysis of the glucocerebrosidase gene in Parkinson's disease
Sato, C., Morgan, A. R., Lang, A. E., Salehi‐Rad, S., Kawarai, T., Meng, Y., Ray, P. N., Farrer, L. A., George‐Hyslop, P. S., & Rogaeva, E. A. (2004) · Movement Disorders · doi:10.1002/mds.20319 · Cited by 125
Cronin, K. D., Ge, D., Manninger, P., Linnertz, C. L., Rossoshek, A., Orrison, B. M., Bernard, D. J., El‐Agnaf, O. M. A., Schlossmacher, M. G., Nussbaum, R. L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp265 · Cited by 123
Self-citationRon, I., Rapaport, D., & Horowitz, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq292 · Cited by 99
The Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Eblan, M. J., Walker, J. M., & Sidransky, E. (2005) · New England Journal of Medicine · doi:10.1056/nejm200502173520719 · Cited by 96
Mirzaei, H., Schieler, J. L., Rochet, J., & Regnier, F. E. (2006) · Analytical Chemistry · doi:10.1021/ac051978n · Cited by 76
Self-citationSun, Y., Quinn, B., Witte, D. P., & Grabowski, G. A. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500202-jlr200 · Cited by 72
Self-citationUrban, D. J., Zheng, W., Göker-Alpan, Ö., Jadhav, A., LaMarca, M. E., Inglese, J., Sidransky, E., & Austin, C. P. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708786734244 · Cited by 46
Cabrera-Salazar, M. A., Bercury, S. D., Ziegler, R. J., Marshall, J., Hodges, B. L., Chuang, W., Pacheco, J., Li, L., Cheng, S. H., & Scheule, R. K. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.07.023 · Cited by 38
Self-citationParkinson's Disease: Assays for the Ubiquitin Ligase Activity of Neural Parkin
Schlossmacher, M. G., & Shimura, H. (2005) · Humana Press eBooks · doi:10.1385/1-59259-895-1:351 · Cited by 19
Self-citationIdentifying Targets in α‐Synuclein Metabolism to Treat Parkinson Disease and Related Disorders
Tomlinson, J. J., Cullen, V., & Schlossmacher, M. G. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch37 · Cited by 7
Self-citation
Cited by
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 868
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
Metadata
- Authors
- Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., Rochet, J., Glicksman, M. A., Cheng, S. H., Grabowski, G. A., Shihabuddin, L. S., & Schlossmacher, M. G.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-04-06
- Volume
- 69
- Issue
- 6
- Pages
- 940-953
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2087968969
- Cited by
- 303
- References
- 41
- FWCI
- 19.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.